Key Highlights

  • AnteoTech (ASX:ADO) shares were up 7.14% at $0.015 during the 22 October 2026 session, as the S&P/ASX 200 fell 0.64%.
  • FY2026 operating expenses, excluding non-cash items, were A$6.86 million, down from A$8.45 million in FY2025.
  • Cash in bank was A$11.2 million at 30 June 2026, with FY2027 priorities centred on sales conversion.

AnteoTech Ltd (ASX:ADO) shares were up 7.14% at $0.015 during the trading session on 22 October 2026, at 11:55 am. The S&P/ASX 200 stood at 8,774.90, down 0.64% (56.40 points), while the All Ordinaries stood at 8,897.80, down 0.66%, at 11:55 am. AnteoTech supplies advanced chemical and material solutions to the battery materials and life sciences markets.

About the Company

AnteoTech Ltd is listed on the ASX under the code ADO and is based in Brisbane, Australia. Merrill Gray is Managing Director and CEO, having been appointed on 19 August 2025, and Glenda McLoughlin is Non-Executive Chair. The company reported 3,265.1 million shares on issue and a market capitalisation of about $56 million as at 23 September 2026.

Its technology is protected through 17 granted patents and is built on a single proprietary binding chemical platform serving two global markets.

Business Overview

The Advanced Battery Technologies business develops products for the lithium-ion battery market. These include the cross-linker Anteo X for high silicon anodes, Anteo S for ceramic coated separators, Anteo C as a performance additive for collector foil primer coatings, SiMRAX (a combination product of Anteo X and single-walled carbon nanotubes), and the Ultranode 70, 95 and X silicon anode formulations.

The Life Sciences business supplies activation materials, under the AnteoBind range, to developers and manufacturers of vaccines and diagnostic tests. AnteoBind NXT is used in point of care tests and in immunoassay formats such as chemiluminescence immunoassays (CLIA) and ELISA plates.

FY2026 Financial Performance

On 30 September 2026, AnteoTech released its FY2026 results and business update presentation, which accompanied a webinar hosted by Mr Gray at 11am AEST that day. Sales revenue was A$467,589 in FY2026, compared with A$968,878 in FY2025 and A$460,397 in FY2024. The FY2025 figure included an additional payment of A$276,863 from Serum Institute of India. A further A$134,138 sale to the institute was completed on 7 July 2026 and will be recognised in FY2027.

Operating expenses, excluding non-cash items such as depreciation, amortisation and share based payments, were A$6,857,881 in FY2026, compared with A$8,451,114 in FY2025 and A$10,892,231 in FY2024. Cash in bank was A$11.2 million at 30 June 2026.

Commercial Progress in the Presentation

The presentation dated 30 September 2026 listed a five-year US$1.8 million contract with Serum Institute of India and an AnteoBind NXT activated ELISA plate prototype under evaluation by the institute. It reported Ultranode X at above 850 mAh/g with 1,020 cycles at 80% capacity retention in-house, Ultranode 95 in a commercial scale-up validation program at the Battery Innovation Center, and commercial cell format evaluation of Ultranode 70 by Wyon.

The presentation also listed multiple sales channels, including partnerships, distributors, conferences and digital marketing. The company said its total addressable market had increased by more than US$60 billion and that it had a record number of samples under evaluation. It also noted joint development agreements for drone anodes under negotiation and SiMRAX in customer trials.

Related Sector Context

Battery materials and diagnostics suppliers typically work through customer evaluations, validation programs and sample testing before commercial volumes are established. In the presentation, the company cited a global diagnostic immunoassays market of US$56 billion and a high silicon anode market of US$540 million, growing at 45% annually.

At 11:55 am on 22 October 2026, the S&P/ASX 200 was down 0.64% and the All Ordinaries down 0.66%, while AnteoTech shares were up 7.14%, moving against the direction of both benchmarks.

Risks to Weigh In

Sales revenue of A$467,589 in FY2026 remains small relative to operating expenses of A$6.86 million. Revenue depends on converting customer evaluations into purchases, which the company lists as its FY2027 priority.

The company's statements note that forward-looking information is subject to risks, uncertainties and assumptions outside its control. Several programs, including the drone battery agreements, are still under negotiation or evaluation, and unlisted options of 233.5 million were on issue as at 23 September 2026, of which 7% expire in 2026 and 65% in 2028.

Catalysts on Watch

The FY2027 priorities in the presentation include converting customer evaluations into sales across India, the US, Europe, Japan and South Korea, progressing US military drone Ultranode 95 joint development agreements, advancing Ultranode 70 commercial cell format evaluation and CLIA and ELISA market entry, and an R&D tax rebate claim.

Commercial engagements listed include MEDICA in Dusseldorf, Germany, and an event at the National Institute of Pharmaceutical Education and Research in Punjab, India, while the North American Battery Show in Detroit ran from 12 to 15 October 2026.

Putting It Together

AnteoTech shares were up 7.14% at $0.015 during the 22 October 2026 session while both benchmarks traded lower. The most recent company update covered here, dated 30 September 2026, set out FY2026 revenue, lower operating expenses and the FY2027 focus on sales conversion.